PMID- 33921222
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210502
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 13
IP  - 8
DP  - 2021 Apr 12
TI  - The Influence of Anti-Diabetic Drugs on Prostate Cancer.
LID - 10.3390/cancers13081827 [doi]
LID - 1827
AB  - The incidences of prostate cancer (PC) and diabetes are increasing, with a 
      sustained trend. The occurrence of PC and type 2 diabetes mellitus (T2DM) is 
      growing with aging. The correlation between PC occurrence and diabetes is 
      noteworthy, as T2DM is correlated with a reduced risk of incidence of prostate 
      cancer. Despite this reduction, diabetes mellitus increases the mortality in many 
      cancer types, including prostate cancer. The treatment of T2DM is based on 
      lifestyle changes and pharmacological management. Current available drugs, except 
      insulin, are aimed at increasing insulin secretion (sulfonylureas, incretin 
      drugs), improving insulin sensitivity (biguanides, thiazolidinediones), or 
      increasing urinary glucose excretion (gliflozin). Comorbidities should be taken 
      into consideration during the treatment of T2DM. This review describes currently 
      known information about the mechanism and impact of commonly used antidiabetic 
      drugs on the incidence and progression of PC. Outcomes of pre-clinical studies 
      are briefly presented and their correlations with available clinical trials have 
      also been observed. Available reports and meta-analyses demonstrate that most 
      anti-diabetic drugs do not increase the risk during the treatment of patients 
      with PC. However, some reports show a potential advantage of treatment of T2DM 
      with specific drugs. Based on clinical reports, use of metformin should be 
      considered as a therapeutic option. Moreover, anticancer properties of metformin 
      were augmented while combined with GLP-1 analogs.
FAU - Knura, Milosz
AU  - Knura M
AUID- ORCID: 0000-0002-4522-2112
AD  - Department of Biochemistry, Faculty of Medical Sciences in Katowice, Medical 
      University of Silesia, Medykow 18, 40-752 Katowice, Poland.
FAU - Garczorz, Wojciech
AU  - Garczorz W
AUID- ORCID: 0000-0002-5343-1205
AD  - Department of Biochemistry, Faculty of Medical Sciences in Katowice, Medical 
      University of Silesia, Medykow 18, 40-752 Katowice, Poland.
FAU - Borek, Adam
AU  - Borek A
AD  - Department of Biochemistry, Faculty of Medical Sciences in Katowice, Medical 
      University of Silesia, Medykow 18, 40-752 Katowice, Poland.
FAU - Drzymala, Franciszek
AU  - Drzymala F
AD  - Department of Biochemistry, Faculty of Medical Sciences in Katowice, Medical 
      University of Silesia, Medykow 18, 40-752 Katowice, Poland.
FAU - Rachwal, Krystian
AU  - Rachwal K
AD  - Department of Biochemistry, Faculty of Medical Sciences in Katowice, Medical 
      University of Silesia, Medykow 18, 40-752 Katowice, Poland.
FAU - George, Kurian
AU  - George K
AD  - Department of Biochemistry, Faculty of Medical Sciences in Katowice, Medical 
      University of Silesia, Medykow 18, 40-752 Katowice, Poland.
FAU - Francuz, Tomasz
AU  - Francuz T
AUID- ORCID: 0000-0002-6321-6090
AD  - Department of Biochemistry, Faculty of Medical Sciences in Katowice, Medical 
      University of Silesia, Medykow 18, 40-752 Katowice, Poland.
LA  - eng
GR  - PCN-1-010/N/0/0/Slaski Uniwersytet Medyczny/
PT  - Journal Article
PT  - Review
DEP - 20210412
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC8068793
OTO - NOTNLM
OT  - DPP-4 inhibitors
OT  - androgen deprivation therapy
OT  - diabetes
OT  - gliflozin
OT  - incretin
OT  - insulin
OT  - metabolic pathway
OT  - metformin
OT  - prostate cancer
OT  - therapy
OT  - thiazolidinediones
COIS- The authors declare no conflict of interest.
EDAT- 2021/05/01 06:00
MHDA- 2021/05/01 06:01
PMCR- 2021/04/12
CRDT- 2021/04/30 01:18
PHST- 2021/02/24 00:00 [received]
PHST- 2021/03/27 00:00 [revised]
PHST- 2021/04/08 00:00 [accepted]
PHST- 2021/04/30 01:18 [entrez]
PHST- 2021/05/01 06:00 [pubmed]
PHST- 2021/05/01 06:01 [medline]
PHST- 2021/04/12 00:00 [pmc-release]
AID - cancers13081827 [pii]
AID - cancers-13-01827 [pii]
AID - 10.3390/cancers13081827 [doi]
PST - epublish
SO  - Cancers (Basel). 2021 Apr 12;13(8):1827. doi: 10.3390/cancers13081827.